Tag
This study identifies plasma proteomic signatures linked to clonal hematopoiesis driver mutations and develops a proteomic risk score that independently predicts adverse clinical outcomes in heart failure with preserved ejection fraction (H
The PORTHOS study reveals a 16.5% prevalence of heart failure among Portuguese adults aged 50+, with HFpEF constituting over 90% of cases, mostly undiagnosed, highlighting the need for enhanced screening strategies in aging populations.
The LIFE-Preserved model accurately predicts short-term and lifetime risks of heart failure hospitalization or cardiovascular death in HFpEF patients, enabling tailored clinical risk stratification and improved management.
This article explores how myeloid cell expansion drives right ventricular dysfunction in HFpEF through sterile inflammation, highlighting translational insights from murine models and human studies.
The TARTAN-HF trial demonstrated that targeted natriuretic peptide screening in high-risk diabetic patients uncovers a high prevalence of undiagnosed heart failure, mainly HFpEF, enabling earlier treatment initiation and improved clinical c
The RELIEVE-HF trial reveals distinct predictors of outcomes after interatrial shunt implantation in HFrEF and HFpEF, enabling personalized risk modeling to identify patients likely to benefit from this therapy.
This article explores the high prevalence of heart failure with preserved ejection fraction (HFpEF) in adults with congenital heart disease (ACHD), highlighting its clinical features, hospitalization burden, and under-treatment issues.
Unclassified pulmonary hypertension often reflects early-stage HFpEF linked to left heart and metabolic dysfunction, identifiable via dynamic right heart catheterization and metabolomics.
Elamipretide improved skeletal muscle force, titin phosphorylation, and atrophy in a HFpEF rat model, supporting cardiolipin stabilization as a promising mitochondrial-targeted strategy.
In a HFpEF rat model, Elamipretide improved muscle force, reduced titin abnormalities, and prevented atrophy, supporting cardiolipin stabilization as a potential strategy for exercise intolerance.
In a HFpEF rat model, elamipretide improved skeletal muscle force, reduced titin hyperphosphorylation, and prevented atrophy, supporting cardiolipin stabilization as a promising metabolic strategy.
In a rat model of HFpEF, the mitochondrial-targeted peptide elamipretide improved skeletal muscle force, reduced atrophy, and normalized titin phosphorylation, supporting cardiolipin stabilization as a promising mechanism.
A Circulation study identifies SRPK3-mediated alternative splicing of TPM1 exon 9a as a driver of myofibrillar disarray, reduced myocardial compliance, and diastolic dysfunction in HFpEF, highlighting a potential disease-modifying therapeut
In FINEARTS-HF, EMPEROR-Preserved biomarker-based risk models showed good prognostic discrimination in HFmrEF/HFpEF, and finerenone’s relative treatment effect was consistent across the full baseline risk spectrum.
In symptomatic HFpEF with atrial functional mitral regurgitation, sacubitril/valsartan improved exercise hemodynamics, peak VO2, symptoms, biomarkers, and stress-induced MR burden over 6 months versus standard care.
A landmark study reveals that exercise-induced multi-organ physiologic deficits strongly predict incident heart failure with preserved ejection fraction (HFpEF). Using invasive cardiopulmonary testing, metabolomics, and genomics across over
The KETO-HFpEF trial demonstrates that while acute ketone ester supplementation effectively induces ketosis and improves resting hemodynamics, it fails to improve peak oxygen consumption or exercise endurance in patients with heart failure
A hemodynamic study of 227 HFpEF patients reveals that 34% exhibit a low-output phenotype. This cold status, especially when combined with congestion, significantly increases mortality risk in overweight and obese individuals, highlighting
A pooled analysis of 21,479 HFpEF/HFmrEF patients reveals that waist-to-height ratio is a superior, linear predictor of mortality and heart failure events compared to BMI. Even in non-obese BMI categories, nearly 90% of patients exhibit exc
A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial elig
